Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Dr Andrew A. Parsons
Director of Reciprocal Minds Limited & Chairman of Pharmasum Therapeutics AS
About the author:
Dr Andrew A Parsons initially trained as a Pharmacologist and Neuroscientist and has over 90 peer reviewed publications, several patents and contributed to Educational Books in Science and Medicine. His former scientific focus was in areas of neuroplasticity and neurodegeneration. He played key roles on individual projects from initial idea through development and the market place. Working across traditional organisational and cultural boundaries he was instrumental in creating External Innovation platforms within a large Pharma company. Through this he became interested the impact of Human Factors on operational processes. He is a member of the Pharmaceutical Special Interest group and an associate member of the Chartered Institute of Ergonomics and Human Factors.
He is the Director of Reciprocal Minds Limited which supports individuals and groups undergoing personal and professional development and challenges to health and wellbeing. He is the co-author of “Leading with Presence, what it is, why it matters and how to get it?” He is also the Chairman of Pharmasum Therapeutics AS, an early stage Biotech company.
Posts by Dr Andrew A. Parsons
Posted on November 14th, 2016 in Pharma R&D
What happened this year? I always thought that even though change can happen quickly, the geopolitical environment would be at a slower, perhaps even glacial pace. Well this year, 2016, has challenged that assumption. (more…)
Posted on October 31st, 2016 in Pharma R&D
Developing a learning culture in any organization can be a challenge, especially in the highly regulated environment of pharma R&D, where people are required to follow protocols and operating procedures. (more…)
Posted on October 7th, 2016 in Pharma R&D
The World Drug Safety Congress took place this month in Munich, and I was very happy to contribute to a panel discussion regarding human factors in drug safety. (more…)
Posted on September 9th, 2016 in Pharma R&D
As a researcher, I spent a considerable amount of my time and energy thinking about (and then conducting) experiments to identify new targets in neurological conditions such as migraine and stroke. (more…)